MA26823A1 - Nouveaux derives de pyrimidine-2,4,6-trione, procede pour leur fabrication et agents pharmaceutiques contenant ces composes. - Google Patents

Nouveaux derives de pyrimidine-2,4,6-trione, procede pour leur fabrication et agents pharmaceutiques contenant ces composes.

Info

Publication number
MA26823A1
MA26823A1 MA26578A MA26578A MA26823A1 MA 26823 A1 MA26823 A1 MA 26823A1 MA 26578 A MA26578 A MA 26578A MA 26578 A MA26578 A MA 26578A MA 26823 A1 MA26823 A1 MA 26823A1
Authority
MA
Morocco
Prior art keywords
compounds
manufacture
pharmaceutical agents
agents containing
novel pyrimidine
Prior art date
Application number
MA26578A
Other languages
English (en)
Inventor
Frank Grams
Herbert Leinert
Ernesto Menta
Hans-Willi Krell
Gerd Zimmermann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26823A1 publication Critical patent/MA26823A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA26578A 1999-10-01 2002-04-01 Nouveaux derives de pyrimidine-2,4,6-trione, procede pour leur fabrication et agents pharmaceutiques contenant ces composes. MA26823A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99119506 1999-10-01

Publications (1)

Publication Number Publication Date
MA26823A1 true MA26823A1 (fr) 2004-12-20

Family

ID=8239103

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26578A MA26823A1 (fr) 1999-10-01 2002-04-01 Nouveaux derives de pyrimidine-2,4,6-trione, procede pour leur fabrication et agents pharmaceutiques contenant ces composes.

Country Status (28)

Country Link
US (1) US6498252B1 (fr)
EP (1) EP1226128B1 (fr)
JP (1) JP3848160B2 (fr)
KR (1) KR100459975B1 (fr)
CN (1) CN1157382C (fr)
AR (1) AR033651A1 (fr)
AT (1) ATE289595T1 (fr)
AU (1) AU768309B2 (fr)
BR (1) BR0014678A (fr)
CA (1) CA2385863C (fr)
CO (1) CO5210860A1 (fr)
CZ (1) CZ20021535A3 (fr)
DE (1) DE60018301T2 (fr)
ES (1) ES2235955T3 (fr)
HU (1) HUP0202832A3 (fr)
IL (1) IL148573A0 (fr)
MA (1) MA26823A1 (fr)
MX (1) MXPA02003192A (fr)
NO (1) NO20021380L (fr)
NZ (1) NZ517635A (fr)
PE (1) PE20010659A1 (fr)
PL (1) PL202680B1 (fr)
RU (1) RU2248971C2 (fr)
TR (1) TR200200858T2 (fr)
UY (1) UY26362A1 (fr)
WO (1) WO2001025217A1 (fr)
YU (1) YU22102A (fr)
ZA (1) ZA200201754B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716845B2 (en) 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
AU2002346729A1 (en) 2001-12-20 2003-07-09 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
WO2004084903A1 (fr) * 2003-03-27 2004-10-07 F. Hoffmann-La Roche Ag Utilisation d'une trioxopyrimidine pour le traitement et la prevention de l'angiogenese pathologique oculaire
WO2004084902A1 (fr) * 2003-03-28 2004-10-07 F. Hoffmann-La Roche Ag Utilisation d'une trioxopyrimidine dans le traitement de lesions chroniques
US20070225253A1 (en) * 2004-04-01 2007-09-27 Didier Cataldo Use of a trioxopyrimidine for the treatment and prevention of bronchial inflammatory diseases
RU2411043C2 (ru) 2004-04-01 2011-02-10 Юниверсите Де Льеж Фармацевтические композиции пиримидин-2,4,6-трионов
EP1632489A1 (fr) * 2004-08-24 2006-03-08 University of Liege Dérivés de 5-(1,1'-Biphényl)-4-yl-5-(4-(4-aminoacylphényl)-pipérazin)-1-yl-pyrimidine-2,4,6-trione comme inhibiteurs de zinc metalloendopeptidase, leur préparation et utilisation.
RU2449994C1 (ru) * 2011-03-10 2012-05-10 Светлана Алексеевна Мещерякова 6-(4-бензилпиперазино)-1,3-диметилурацила дигидрохлорид, проявляющий биологическую активность
RU2598607C1 (ru) * 2015-07-16 2016-09-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный университет" (Астраханский государственный университет) Способ получения 5-гетарилметиленпиримидин-2,4,6-трионов

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1246743B (de) * 1965-01-12 1967-08-10 Dresden Arzneimittel Verfahren zur Herstellung von 5-Phenyl-5-piperidinobarbitursaeuren
US4595700A (en) 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
GB8726714D0 (en) 1987-11-14 1987-12-16 Beecham Group Plc Compounds
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
ATE120182T1 (de) 1990-12-03 1995-04-15 Celltech Ltd Peptidylderivate.
CA2058797A1 (fr) 1991-02-01 1992-08-02 Michael John Broadhurst Derives d'aminoacide
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
ES2233275T3 (es) 1995-12-08 2005-06-16 Agouron Pharmaceuticals, Inc. Intermediarios que sirven para la preparacion de inhibidores de metaloproteinasas.
DE19548624A1 (de) * 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers

Also Published As

Publication number Publication date
JP3848160B2 (ja) 2006-11-22
AU768309B2 (en) 2003-12-04
IL148573A0 (en) 2002-09-12
WO2001025217A1 (fr) 2001-04-12
PE20010659A1 (es) 2001-06-20
HUP0202832A3 (en) 2003-03-28
TR200200858T2 (tr) 2002-07-22
KR20020039356A (ko) 2002-05-25
EP1226128B1 (fr) 2005-02-23
ES2235955T3 (es) 2005-07-16
JP2003511376A (ja) 2003-03-25
NZ517635A (en) 2003-11-28
CA2385863C (fr) 2009-04-14
UY26362A1 (es) 2001-04-30
MXPA02003192A (es) 2002-09-30
CZ20021535A3 (cs) 2002-11-13
PL357385A1 (en) 2004-07-26
CN1374954A (zh) 2002-10-16
ATE289595T1 (de) 2005-03-15
NO20021380D0 (no) 2002-03-20
HK1050198A1 (en) 2003-06-13
CN1157382C (zh) 2004-07-14
EP1226128A1 (fr) 2002-07-31
US6498252B1 (en) 2002-12-24
ZA200201754B (en) 2003-06-02
KR100459975B1 (ko) 2004-12-03
AR033651A1 (es) 2004-01-07
AU7784900A (en) 2001-05-10
CA2385863A1 (fr) 2001-04-12
DE60018301T2 (de) 2006-04-06
BR0014678A (pt) 2002-07-23
YU22102A (sh) 2004-11-25
RU2248971C2 (ru) 2005-03-27
CO5210860A1 (es) 2002-10-30
PL202680B1 (pl) 2009-07-31
HUP0202832A2 (hu) 2003-02-28
NO20021380L (no) 2002-03-20
DE60018301D1 (de) 2005-03-31

Similar Documents

Publication Publication Date Title
MA26472A1 (fr) Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2729951B1 (fr) Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
MA26686A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA25493A1 (fr) Derives de 3(5)-amino-pyrazole, procede pour leur preparation et leur utilisation en tant qu'agents antitumoraux.
MA26424A1 (fr) Derives de 6-phenylpyridyl-2-amine, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26432A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26414A1 (fr) Derives de quinoleine et de quinazoline nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant.
MA26471A1 (fr) Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26415A1 (fr) Composes heterocycliques, procede pour la preparation et compositions pharmaceutiques les contenant
MA26680A1 (fr) Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26712A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26499A1 (fr) Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant .
MA26687A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26558A1 (fr) Derives nouveaux de 6-0-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26452A1 (fr) Derives de pyrimidine bicycliques condenses, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26740A1 (fr) Derives de 13-methyl-erythromycine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26614A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26653A1 (fr) Pyrrolo [2,3- d] pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26479A1 (fr) Derives de nicotinamide, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26468A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26438A1 (fr) Derives 6,5-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2816938B1 (fr) Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
MA26519A1 (fr) Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant.
DZ2866A1 (fr) 1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26624A1 (fr) Derives de quinazolinamines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant